First Time Loading...

Simulations Plus Inc
NASDAQ:SLP

Watchlist Manager
Simulations Plus Inc Logo
Simulations Plus Inc
NASDAQ:SLP
Watchlist
Price: 46.13 USD 1.72% Market Closed
Updated: May 1, 2024
Section:
 

Relative Value

The Relative Value of one SLP stock under the Base Case scenario is 17.12 USD. Compared to the current market price of 46.13 USD, Simulations Plus Inc is Overvalued by 63%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SLP Relative Value
Base Case
17.12 USD
Overvaluation 63%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

14.3
P/S
P/S
Price to Sales
14.3
vs History
80
vs Industry
10
Median 3Y
16.9
Median 5Y
17.6
Industry
2.4
Forward
13.4
More Details
87.7
P/E
P/E
Price to Earnings
87.7
vs History
40
vs Industry
5
Median 3Y
83.3
Median 5Y
81.2
Industry
23.2
Forward
69.6
More Details
52.4
P/OCF
P/OCF
Price to OCF
52.4
vs History
50
vs Industry
6
Median 3Y
47.2
Median 5Y
51.6
Industry
15.5
More Details
72.2
P/FCFE
P/FCFE
Price to FCFE
72.2
vs History
40
vs Industry
8
Median 3Y
65
Median 5Y
65.7
Industry
23.5
More Details
5.2
P/B
P/B
Price to Book Value
5.2
vs History
72
vs Industry
16
Median 3Y
5.3
Median 5Y
6
Industry
2.2
More Details
12.6
EV/S
EV/S
Enterprise Value to Sales
12.6
vs History
82
vs Industry
11
Median 3Y
14.3
Median 5Y
15.8
Industry
2.5
Forward
11.8
More Details
16.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
16.7
vs History
75
vs Industry
12
Median 3Y
18.5
Median 5Y
20.4
Industry
5.2
More Details
60.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
60.7
vs History
25
vs Industry
4
Median 3Y
51.9
Median 5Y
51.4
Industry
12.5
Forward
34
More Details
88.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
88.2
vs History
20
vs Industry
3
Median 3Y
70.1
Median 5Y
67.7
Industry
17.2
Forward
64.9
More Details
46.3
EV/OCF
EV/OCF
Enterprise Value to OCF
46.3
vs History
50
vs Industry
7
Median 3Y
41
Median 5Y
45.7
Industry
15.1
More Details
63.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
63.7
vs History
41
vs Industry
7
Median 3Y
55.7
Median 5Y
60
Industry
19.7
More Details
9.6
EV/IC
EV/IC
Enterprise Value to IC
9.6
vs History
90
vs Industry
9
Median 3Y
13.2
Median 5Y
14.1
Industry
2
More Details

Multiples Across Competitors

SLP Competitors Multiples
Simulations Plus Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Simulations Plus Inc
NASDAQ:SLP
921.8m USD 14.3 87.7 60.7 88.2
US
Veeva Systems Inc
NYSE:VEEV
32.1B USD 13.6 61.1 60.9 65.5
US
Cerner Corp
NASDAQ:CERN
27.9B USD 4.8 47.3 19.6 38.6
US
Change Healthcare Inc
NASDAQ:CHNG
9B USD 2.6 -116.8 16.5 111.6
AU
Pro Medicus Ltd
ASX:PME
11.4B AUD 78.1 163.7 112.5 112.5
US
Inspire Medical Systems Inc
NYSE:INSP
7.2B USD 11.5 -340.1 -179.9 -167.2
JP
M3 Inc
TSE:2413
1.1T JPY 4.8 24.2 12.6 14.2
US
Doximity Inc
NYSE:DOCS
4.5B USD 9.7 33 22.1 23.5
SE
Sectra AB
STO:SECT B
42.2B SEK 25.8 99.5 -65.5 -65.5
US
Evolent Health Inc
NYSE:EVH
3.1B USD 1.6 -22.1 26.1 277.4
US
Goodrx Holdings Inc
NASDAQ:GDRX
2.8B USD 3.7 -311.1 33.2 -108.4
P/E Multiple
Earnings Growth
US
Simulations Plus Inc
NASDAQ:SLP
Average P/E: 73.8
87.7
N/A
US
Veeva Systems Inc
NYSE:VEEV
61.1
139%
US
Cerner Corp
NASDAQ:CERN
47.3
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
Negative Multiple: -116.8 N/A
AU
Pro Medicus Ltd
ASX:PME
163.7
119%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -340.1 N/A
JP
M3 Inc
TSE:2413
24.2
26%
US
Doximity Inc
NYSE:DOCS
33
79%
SE
Sectra AB
STO:SECT B
99.5
56%
US
Evolent Health Inc
NYSE:EVH
Negative Multiple: -22.1 N/A
US
Goodrx Holdings Inc
NASDAQ:GDRX
Negative Multiple: -311.1 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Simulations Plus Inc
NASDAQ:SLP
Average EV/EBITDA: 40.5
60.7
N/A
US
Veeva Systems Inc
NYSE:VEEV
60.9
221%
US
Cerner Corp
NASDAQ:CERN
19.6
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
16.5
N/A
AU
Pro Medicus Ltd
ASX:PME
112.5
124%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -179.9 N/A
JP
M3 Inc
TSE:2413
12.6
24%
US
Doximity Inc
NYSE:DOCS
22.1
103%
SE
Sectra AB
STO:SECT B
Negative Multiple: -65.5 N/A
US
Evolent Health Inc
NYSE:EVH
26.1
194%
US
Goodrx Holdings Inc
NASDAQ:GDRX
33.2
305%
EV/EBIT Multiple
EBIT Growth
US
Simulations Plus Inc
NASDAQ:SLP
Average EV/EBIT: 91.4
88.2
170%
US
Veeva Systems Inc
NYSE:VEEV
65.5
238%
US
Cerner Corp
NASDAQ:CERN
38.6
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
111.6
N/A
AU
Pro Medicus Ltd
ASX:PME
112.5
110%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -167.2 N/A
JP
M3 Inc
TSE:2413
14.2
N/A
US
Doximity Inc
NYSE:DOCS
23.5
116%
SE
Sectra AB
STO:SECT B
Negative Multiple: -65.5 N/A
US
Evolent Health Inc
NYSE:EVH
277.4
2 086%
US
Goodrx Holdings Inc
NASDAQ:GDRX
Negative Multiple: -108.4 N/A

See Also

Summary
SLP intrinsic value, competitors valuation, and company profile.
DCF Valuation
SLP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SLP stock valuation using valuation multiples.
Wall Street Estimates
SLP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SLP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.